Comparative Trial of Pivanex and Docetaxel Vs Docetaxel Monotherapy in Patients With Advanced Non-Small Cell Lung Cancer
Status:
Completed
Trial end date:
2004-10-01
Target enrollment:
Participant gender:
Summary
This randomized study will assess the efficacy and safety of the combination of Pivanex and
docetaxel compared to docetaxel alone in patients with a type of lung cancer called non-small
cell lung cancer. Pivanex is an investigational agent, and docetaxel is an approved drug.